A Descriptive Register of ANCA ‑PositiveVasculitis Patients with Kidney Involvement:A Portuguese Center Experience over 13Years
DOI:
https://doi.org/10.71749/pkj.74Palavras-chave:
Anti‑Neutrophil Cytoplasmic Antibody‑Associated Vasculitis/drug therapy, Anti‑Neutrophil Cytoplasmic Antibody‑Associated Vasculitis/complications, Glomerulonephritis, Kidney DiseasesResumo
Introduction: Anti‑neutrophil cytoplasm antibody (ANCA)‑associated vasculitis (AAV) is a necrotizing disease affecting small blood vessels, commonly involving the kidneys, and associated with high morbidity and mortality.</p>
Methods: We conducted a descriptive cross‑sectional study at Hospital de São João in Porto, including patients aged 18 or older with biopsy‑proven kidney involvement from AAV, followed by a multidisciplinary team from December 2010 to June 2023. We analyzed demographic, clinical, and laboratory variables, kidney pathology findings, treatment regimens, and patient outcomes.</p>
Results: Fifty‑one patients were included, with a median age of 66 years (IQR, 56‑74) and a male predominance (61%). Most patients (78%) had myeloperoxidase (MPO)‑associated AAV. Chronic kidney disease (CKD) was present in 18% of cases, and 96% presented with rapidly progressive glomerulonephritis (RPGN). Hemodialysis was required in 29% of cases. Induction therapy consisted of cyclophosphamide and glucocorticoids in 86%, with a median cyclophosphamide dose of 6 g (IQR, 3.25‑8.25). After 2020, five patients received rituximab plus glucocorticoids. Plasma exchange was performed in 12 patients (nine with alveolar hemorrhage). Maintenance therapy included azathioprine in 32 patients and rituximab in six patients. Of patients requiring hemodialysis, 40% recovered kidney function. During follow‑up, 39% of patients progressed to end‑stage kidney disease, ten patients (20%) relapsed, and 17 died (33%).
Conclusion: This study provides valuable insights into the epidemiology, treatment, and outcomes of AAV with kidney involvement in Portugal. Further studies are needed to optimize treatment strategies across more centers.
Downloads
Referências
Fries JF, Hunder GG, Bloch DA, Michel BA, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum. 1990;33:1135‑6.
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1‑11.
Sinico RA, Di Toma L, Radice A. Renal involvement in anti‑neutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev. 2013;12:477‑82. doi: 10.1016/j.autrev.2012.08.006.
Solans‑Laqué R, Fraile G, Rodriguez‑Carballeira M, Caminal L, Castillo MJ, Martínez‑Valle F, et al. Clinical characteristics and outcome of Spanish patients with ANCA‑associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. Medicine. 2017;96:e6083. doi: 10.1097/MD.0000000000006083.
Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81:315‑20. doi: 10.1136/annrheumdis‑2021‑221795.
Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022;81:321‑6. doi: 10.1136/annrheumdis‑2021‑221796.
Domingues VM, Machado B, Santos J. ANCA‑positive vasculitis: Clinical implications of ANCA types and titers. Rev Assoc Med Bras. 2016;62:434‑40. doi: 10.1590/1806‑9282.62.05.434.
Ponte C, Khmelinskii N, Teixeira V, Luz K, Peixoto D, Rodrigues M, et al. Reuma.pt/vasculitis ‑ the Portuguese vasculitis registry. Orphanet J Rare Dis. 2020;15:110. doi: 10.1186/s13023‑020‑01381‑0.
Fonseca JA, Gameiro J, Duarte I, Jorge S, Lopes JA. The neutrophil‑to‑lymphocyte ratio as a marker of vasculitis activity, severe infection and mortality in ANCA‑associated vasculitis: A retrospective study. Nefrologia. 2021;41:321‑8. doi: 10.1016/j.nefroe.2021.07.005.
Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, et al. Histopathologic classification of ANCA‑associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628‑36. doi: 10.1681/ASN.2010050477.
Brix SR, Noriega M, Tennstedt P, Vettorazzi E, Busch M, Nitschke M, et al. Development and validation of a renal risk score in ANCA‑associated glomerulonephritis. Kidney Int. 2018;94:1177‑88. doi: 10.1016/j.kint.2018.07.020.
Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA‑associated vasculitis: long‑term follow‑up. Ann Rheum Dis. 2012;71:955‑60. doi: 10.1136/annrheumdis‑2011‑200477.
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA‑associated vasculitis. N Engl J Med. 2010;363:221‑32. doi: 10.1056/NEJMoa0909905.
Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA‑associated renal vasculitis. N Engl J Med. 2010;363:211‑20.
Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA‑associated vasculitis. N Engl J Med. 2020;382:622‑31. doi: 10.1056/NEJMoa1803537.
Ferreira I, Águeda A, Belino C, Schau B, Rovisco J, Ferreira C. Insights from Portuguese Nephrologists and Rheumatologists Concerning the Treatment of ANCA Vasculitis. Acta Med Port. 2024;37:778‑86. doi: 10.20344/amp.21635.
Mohammad AJ. An update on the epidemiology of ANCA‑associated vasculitis. Rheumatology. 2020;59:iii42‑iii50.
Pearce FA, Craven A, Merkel PA, Luqmani RA, Watts RA. Global ethnic and geographic differences in the clinical presentations of anti‑neutrophil cytoplasm antibody‑associated vasculitis. Rheumatology. 2017;56:1962‑9. doi: 10.1093/rheumatology/kex293.
KDIGO 2024 Clinical Practice Guideline for the Management of antineutrophil cytoplasmic antibody (ANCA)‑associated vasculitis. Kidney Int. 2024;105:S71‑s116. doi: 10.1016/j.kint.2023.10.008.
Santos A, Figueiredo R, Paulo N, Marques N, Pereira E, Mariz E, et al. #675 Application of ANCA‑associated vasculitis Histopathological Classification and Renal Risk Score for prediction of end‑stage kidney disease. Nephrol Dial Transplant. 2024;39: gfae069‑0334‑675. doi: 10.1093/ndt/gfae069.334.
Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98:76‑85. doi: 10.7326/0003‑4819‑98‑1‑76.
Jayne DR, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA‑associated vasculitis. N Engl J Med. 2021;384:599‑609. doi: 10.1056/NEJMoa2023386. Erratum in: N Engl J Med. 2024;390:388. doi: 10.1056/NEJMx230010.
Downloads
Publicado
Edição
Secção
Licença
Direitos de Autor (c) 2025 Adriana Santos, Núria Paulo, Nídia Marques, Rafael Figueiredo, Ana Pinho, Edite Pereira, Eva Mariz, Ricardo Neto, Inês Ferreira
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição-NãoComercial 4.0.
